Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 118 participants.

Also called NCT04040959

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 118 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04040959
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04040959. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-19 (actual); primary completion 2026-07-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
Condition
Vascular Diseases
Condition
Kidney Disease
Condition
Blood Pressure
Condition
Oxidative Stress
Intervention (Drug)
Nicotinamide riboside
Lead sponsor
University of Colorado, Denver (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04040959
Content hash
fc08e2b963fb1d460c7064f86a849963d88fc92b13cbb8d9fcab82ff3366f3aa